Enhanced Ca2(+)-dependent proteolysis associated with Adriamycin-resistant HL-60 cells. 1990

A Aquino, and M Johnson-Thompson, and R I Glazer
Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Adriamycin-resistant HL-60 (HL-60/ADR) cells possess high constitutive levels of the proteolytically generated catalytic fragment of protein kinase C, M-kinase, resulting in the generation of pp130 in vitro. In this report, we have demonstrated the presence of a Ca2(+)-activated protease in extracts from HL-60/ADR cells, but not in wild-type cells, which resulted in the generation of 26 and 86 kDa phosphoproteins in vitro, as well as in the reduction of pp130. The formation of pp26 and pp86 and the reduction in pp130 were prevented by the serine/cysteine protease inhibitor, leupeptin. A 26 kDa phosphoprotein with a similar isoelectric point was also evident in both cell lines following metabolic labeling in vivo, although the phosphorylation of pp26 was much greater in resistant cells. These data suggest that the presence of Ca2(+)-dependent protease activity is a phenotypic characteristic of this multidrug resistant cell line.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D010750 Phosphoproteins Phosphoprotein
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug

Related Publications

A Aquino, and M Johnson-Thompson, and R I Glazer
July 2007, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
A Aquino, and M Johnson-Thompson, and R I Glazer
February 1994, Journal of bioenergetics and biomembranes,
A Aquino, and M Johnson-Thompson, and R I Glazer
January 2017, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
A Aquino, and M Johnson-Thompson, and R I Glazer
January 1990, Biochemical and biophysical research communications,
A Aquino, and M Johnson-Thompson, and R I Glazer
June 1988, Cancer research,
A Aquino, and M Johnson-Thompson, and R I Glazer
October 2009, Zhongguo shi yan xue ye xue za zhi,
A Aquino, and M Johnson-Thompson, and R I Glazer
January 1985, Leukemia research,
A Aquino, and M Johnson-Thompson, and R I Glazer
December 1986, Blood,
A Aquino, and M Johnson-Thompson, and R I Glazer
July 1988, Cancer biochemistry biophysics,
A Aquino, and M Johnson-Thompson, and R I Glazer
January 1996, Cellular signalling,
Copied contents to your clipboard!